Tactical Therapeutics - Angiogenesis

Press Release

Special Biotechnology Report
24 June 2009,
Washington Post.
Click here to download the pdf

BIOWIRE 2K,
9 May 2006 ,
Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006

RESEARCH & Development

Angiogenesis

Tactical’s CTO is an important candidate for cancer therapy because CAI has been shown to

	Inhibit angiogenesis, inhibit intracellular calcium influx, inhibit signal transduction and ultimately down-regulation of the production of regulatory proteins responsible for tumor invasion and metastases,
	Inhibit VEGF, production and anti-VEGF1
	Tactical’s CTO has comparable anti-tumoractivity to AVASTIN as monotherapy, but greater efficacy when each is given in combination with S-FU